MedTrace Logo

Endothelial Glycocalyx in Patients With Chronic Kidney Disease

NCT04363567 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 137

Last updated 2020-04-27

No results posted yet for this study

Summary

The luminal side of the entire vasculature is covered with a gel-like polymer called endothelial glycocalyx (EG). EG is important for the transport of molecules in and out of the blood cells and for endothelial function. EG protects the blood vessel wall, is likely to contribute to maintenance of normal blood pressure and the prevention of blood clot formation. Overall it is likely to avoid development of cardiovascular disease.

A newly developed blood test, salt-blood test, can measure erythrocyte salt sensitivity and gives information about the condition of EG. EG can also be measured by release of endothelial glycocalyx proteins.

Previous studies indicate that this EG is impaired by a number of chronic diseases, including chronic kidney disease. This study investigates the quality of glycocalyx in patients with chronic kidney disease, and compares with the layer in healthy.

Conditions

  • Healthy
  • Chronic Kidney Diseases

Sponsors & Collaborators

  • Regional Hospital Holstebro

    lead OTHER

Principal Investigators

  • Rikke Lu Sønderbæk, MD · Department of medical research and medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-07
Primary Completion
2019-06-25
Completion
2019-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04363567 on ClinicalTrials.gov